name: | CefepimeAndBetaLactamaseInhibitor |
ATC code: | J01DE51 | route: | intravenous |
n-compartments | 2 |
Cefepime is a fourth-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It is often combined with a beta-lactamase inhibitor (such as tazobactam or zidebactam) to extend its activity against beta-lactamase-producing bacteria. These combinations are typically used in treatment of complicated urinary tract infections, hospital-acquired pneumonia, and other serious infections. As of now, cefepime-beta-lactamase inhibitor combinations (ATC J01DE51) are not widely approved as co-formulations, and clinical use may be limited to investigational or compassionate settings.
No published pharmacokinetic data available specifically for cefepime and a beta-lactamase inhibitor combination. The following parameters are estimated based on known pharmacokinetics of cefepime (adult, intravenous administration, normal renal function) and commonly used beta-lactamase inhibitors.
Zhanel, GG, et al., & Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 79(3) 271–289. DOI:10.1007/s40265-019-1055-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30712199
Das, S, et al., & Hope, W (2020). Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. Antimicrobial agents and chemotherapy 65(1) –. DOI:10.1128/AAC.01468-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33077666
Chen, M, et al., & Fahim, G (2019). Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 76(18) 1383–1394. DOI:10.1093/ajhp/zxz154 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31505562